Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study

Giovanni Frisullo, Massimiliano Calabrese, Carla Tortorella, Damiano Paolicelli, Paolo Ragonese, Pietro Annovazzi, Marta Radaelli, Simona Malucchi, Antonio Gallo, Valentina Tomassini, Viviana Nociti, Mariangela D'Onghia, Vincenzina Lo Re, Mariemma Rodegher, Claudio Solaro, Claudio Gasperini

Research output: Contribution to journalArticlepeer-review

Abstract

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.

Original languageEnglish
Pages (from-to)1265-1268
Number of pages4
JournalMultiple Sclerosis Journal
Volume20
Issue number9
DOIs
Publication statusPublished - 2014

Keywords

  • Adverse effects
  • autoimmunity
  • glatiramer acetate
  • interferon beta
  • multiple sclerosis
  • thyroid

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study'. Together they form a unique fingerprint.

Cite this